This April-2025 post snowballed after a pre-print suggested semaglutide’s anti-inflammatory profile could benefit secondary lymphedema. Endocrinologists highlighted rapid weight-loss–mediated improvements in venous return, whereas basic-science voices pointed to GLP-1–induced macrophage polarization that might soften indurated tissue. A vascular surgeon cautioned about malnutrition-related wound-healing delays in post-cancer limbs. The crowd agreed that the forthcoming, 40-patient randomized trial (enrollment now open) must stratify by BMI and stage to tease out direct versus indirect drug effects.
24 May 2025 — la discussione potrebbe continuare visita reddit
